Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Darbepoetin alfa

Darbepoetin alfa

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Darbepoetin alfa

39 trials tracked of Darbepoetin alfa: 31 in phase 3 or 4 and 7 with published results. The most-cited published study has 237 citations.

39Trials tracked
31Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 3 Phase 3 28 Phase 2 6 Phase 1 1 Other / NA 1
  1. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) Completed · 237 cited
  2. Phase 3 Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease Completed · 237 cited
  3. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Completed · 217 cited
  4. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD) Completed · 195 cited
  5. Phase 3 Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD) Completed · 195 cited
  6. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Completed · 73 cited
Show 33 more trials
  1. Phase 3 Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs) Completed · 49 cited
  2. Phase 4 Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients Completed
  3. Phase 4 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) Completed
  4. Phase 4 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed
  5. Phase 3 Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan Completed
  6. Phase 3 A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia Completed
  7. Phase 3 A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients Completed
  8. Phase 3 A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients. Completed
  9. Phase 3 A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis. Completed
  10. Phase 3 RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial Completed
  11. Phase 3 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis Completed
  12. Phase 3 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed
  13. Phase 3 Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease Completed
  14. Phase 3 Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients Completed
  15. Phase 3 Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT) Completed
  16. Phase 3 Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease Completed
  17. Phase 3 Darbepoetin Alfa MDS Companion Protocol Completed
  18. Phase 3 A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Completed
  19. Phase 3 A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis Completed
  20. Phase 3 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed
  21. Phase 3 Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan Completed
  22. Phase 3 A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients. Completed
  23. Phase 3 Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Completed
  24. Phase 3 Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa Completed
  25. Phase 3 Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Completed
  26. Phase 2 Darbepoetin Alfa With or Without Intravenous (IV) Iron Completed
  27. Phase 2 Darbe Administration in Newborns Undergoing Cooling for Encephalopathy Completed
  28. Phase 2 Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma Completed
  29. Phase 2 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed
  30. Phase 2 Mild Encephalopathy in the Newborn Treated With Darbepoetin Completed
  31. Phase 2 The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial Completed
  32. Phase 1 Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers Completed
  33. N/A Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease Completed

Showing the 39 most-cited and recently-updated of 39 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.